Congress blasts FDA’s Aduhelm approval as ‘rife with irregularities’
U.S. health officials’ approval process for Biogen Inc.’s controversial Alzheimer’s drug was “rife with irregularities,” raising serious concerns about protocol lapses at the agency, congressional investigators said. The Food and …
Congress blasts FDA’s Aduhelm approval as ‘rife with irregularities’ Read More